نتائج البحث - "Adam Gibb"

المصدر: Radford, J 2020, ' Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY) ', British Jounal Haematology . https://doi.org/10.1111/bjh.17073

مصطلحات موضوعية: Male, medicine.medical_specialty, Randomization, Anemia, Phases of clinical research, Comorbidity, Fostamatinib, Placebo, Gastroenterology, elderly, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, Drug Therapy, Internal medicine, Positron Emission Tomography Computed Tomography, medicine, Biomarkers, Tumor, Humans, Brentuximab vedotin, Aged, Neoplasm Staging, Aged, 80 and over, Brentuximab Vedotin, biology, Dose-Response Relationship, Drug, Frailty, business.industry, Haptoglobin, Age Factors, Hematology, medicine.disease, Hodgkin Disease, Progression-Free Survival, United Kingdom, Warm antibody autoimmune hemolytic anemia, Treatment Outcome, 030220 oncology & carcinogenesis, biology.protein, Female, Safety, business, brentuximab Vedotin, Hodgkin lymphoma, 030215 immunology, medicine.drug

وصف الملف: text

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::765e2143350ae540624136426f1106dd
https://doi.org/10.1111/bjh.17073

6

Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma

المصدر: Booth, S, Plaschkes, H, Kirkwood, A A, Gibb, A, Horgan, P, Higham, C, Oladipo, J M, Browning, J, Khan, U, Tseu, B, Chen, L, Willan, J, Wolf, J, Gunawan, A, Fields, P, Ebsworth, T, Lown, R, Gordon-Walker, D, Shah, N, Linton, K M, Collins, G P, Kothari, J, Hildyard, C & Eyre, T A 2020, ' Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma ', Blood Advances, vol. 4, no. 18, pp. 4337-4346 . https://doi.org/10.1182/BLOODADVANCES.2020002553
Blood Adv

مصطلحات موضوعية: medicine.medical_specialty, Vincristine/adverse effects, Osteoporosis, Cyclophosphamide/adverse effects, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Rituximab/adverse effects, medicine, Humans, Cyclophosphamide, Aged, Retrospective Studies, 030203 arthritis & rheumatology, Lymphoid Neoplasia, Manchester Cancer Research Centre, business.industry, Incidence (epidemiology), Antineoplastic Combined Chemotherapy Protocols/adverse effects, ResearchInstitutes_Networks_Beacons/mcrc, Retrospective cohort study, Hematology, medicine.disease, Osteopenia, Lymphoma, Large B-Cell, Diffuse/drug therapy, Doxorubicin, Vincristine, 030220 oncology & carcinogenesis, Rheumatoid arthritis, Prednisolone, Rituximab, Lymphoma, Large B-Cell, Diffuse, Doxorubicin/adverse effects, business, Diffuse large B-cell lymphoma, medicine.drug